PL2536764T3 - Humanizowane przeciwciała anty-CD28 - Google Patents
Humanizowane przeciwciała anty-CD28Info
- Publication number
- PL2536764T3 PL2536764T3 PL11707918T PL11707918T PL2536764T3 PL 2536764 T3 PL2536764 T3 PL 2536764T3 PL 11707918 T PL11707918 T PL 11707918T PL 11707918 T PL11707918 T PL 11707918T PL 2536764 T3 PL2536764 T3 PL 2536764T3
- Authority
- PL
- Poland
- Prior art keywords
- humanized antibodies
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290080A EP2361935A1 (en) | 2010-02-18 | 2010-02-18 | Anti-CD28 humanized antibodies |
| EP10290389 | 2010-07-13 | ||
| EP11707918.6A EP2536764B1 (en) | 2010-02-18 | 2011-02-16 | Anti-cd28 humanized antibodies |
| PCT/IB2011/050646 WO2011101791A1 (en) | 2010-02-18 | 2011-02-16 | Anti-cd28 humanized antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2536764T3 true PL2536764T3 (pl) | 2018-12-31 |
Family
ID=44482493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11707918T PL2536764T3 (pl) | 2010-02-18 | 2011-02-16 | Humanizowane przeciwciała anty-CD28 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8785604B2 (pl) |
| EP (2) | EP2536764B1 (pl) |
| JP (1) | JP5992340B2 (pl) |
| CA (1) | CA2788544C (pl) |
| CY (1) | CY1120707T1 (pl) |
| DK (1) | DK2536764T3 (pl) |
| ES (2) | ES2680570T3 (pl) |
| HR (1) | HRP20181360T1 (pl) |
| HU (1) | HUE039677T2 (pl) |
| LT (1) | LT2536764T (pl) |
| PL (1) | PL2536764T3 (pl) |
| PT (1) | PT2536764T (pl) |
| RS (1) | RS57667B1 (pl) |
| SI (1) | SI2536764T1 (pl) |
| SM (1) | SMT201800462T1 (pl) |
| TR (1) | TR201811185T4 (pl) |
| WO (1) | WO2011101791A1 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
| PL2536764T3 (pl) | 2010-02-18 | 2018-12-31 | Ose Immunotherapeutics | Humanizowane przeciwciała anty-CD28 |
| WO2014120916A1 (en) * | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
| SG10201804750XA (en) * | 2013-12-06 | 2018-07-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 |
| RS61958B1 (sr) * | 2015-12-15 | 2021-07-30 | Ose Immunotherapeutics | Anti-cd28 humanizovana antitela formulisana za primenu na ljudima |
| CA3029977A1 (en) * | 2016-07-06 | 2018-01-11 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| JP2019522486A (ja) | 2016-07-13 | 2019-08-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP7773528B2 (ja) | 2020-08-19 | 2025-11-19 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| KR20240107093A (ko) | 2021-08-05 | 2024-07-08 | 고 테라퓨틱스, 인크. | 항-글리코-muc4 항체 및 그의 용도 |
| KR20240109604A (ko) | 2021-09-03 | 2024-07-11 | 고 테라퓨틱스, 인크. | 항-글리코-cMET 항체 및 그의 용도 |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｌａｍｐ１抗体およびその使用 |
| CN118829725A (zh) | 2021-10-28 | 2024-10-22 | 莱尔免疫制药公司 | 生成细胞的方法 |
| WO2023114701A2 (en) * | 2021-12-13 | 2023-06-22 | BioLegend, Inc. | Cd28 binding antibodies and antigen binding fragments thereof |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
| CN119735680B (zh) * | 2024-12-12 | 2025-07-29 | 北京同立海源生物科技有限公司 | 一种抗cd28的单克隆抗体及细胞 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| HUP0400697A3 (en) * | 2000-12-14 | 2007-05-02 | Astellas Pharma Inc | Silensed anti-cd28 antibodies and use thereof |
| DE60142794D1 (de) | 2000-12-26 | 2010-09-23 | Inst Nat Sante Rech Med | Antikörper gegen cd28 |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| TW200732350A (en) * | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| SI2700651T1 (sl) * | 2008-07-18 | 2019-08-30 | Bristol-Myers Squibb Company | Monovalentni sestavki za vezavo CD28 in postopki uporabe |
| CN102257001A (zh) * | 2008-12-19 | 2011-11-23 | 诺瓦提斯公司 | 治疗自体免疫和炎性病症的可溶性多肽 |
| EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
| PL2536764T3 (pl) * | 2010-02-18 | 2018-12-31 | Ose Immunotherapeutics | Humanizowane przeciwciała anty-CD28 |
| RS61958B1 (sr) * | 2015-12-15 | 2021-07-30 | Ose Immunotherapeutics | Anti-cd28 humanizovana antitela formulisana za primenu na ljudima |
-
2011
- 2011-02-16 PL PL11707918T patent/PL2536764T3/pl unknown
- 2011-02-16 PT PT117079186T patent/PT2536764T/pt unknown
- 2011-02-16 SM SM20180462T patent/SMT201800462T1/it unknown
- 2011-02-16 TR TR2018/11185T patent/TR201811185T4/tr unknown
- 2011-02-16 HU HUE11707918A patent/HUE039677T2/hu unknown
- 2011-02-16 WO PCT/IB2011/050646 patent/WO2011101791A1/en not_active Ceased
- 2011-02-16 RS RS20180994A patent/RS57667B1/sr unknown
- 2011-02-16 JP JP2012553431A patent/JP5992340B2/ja active Active
- 2011-02-16 DK DK11707918.6T patent/DK2536764T3/en active
- 2011-02-16 ES ES11707918.6T patent/ES2680570T3/es active Active
- 2011-02-16 LT LTEP11707918.6T patent/LT2536764T/lt unknown
- 2011-02-16 CA CA2788544A patent/CA2788544C/en active Active
- 2011-02-16 EP EP11707918.6A patent/EP2536764B1/en active Active
- 2011-02-16 ES ES18177022T patent/ES2896149T3/es active Active
- 2011-02-16 EP EP18177022.3A patent/EP3428192B1/en active Active
- 2011-02-16 HR HRP20181360TT patent/HRP20181360T1/hr unknown
- 2011-02-16 US US13/577,103 patent/US8785604B2/en active Active
- 2011-02-16 SI SI201131521T patent/SI2536764T1/sl unknown
-
2014
- 2014-07-08 US US14/326,119 patent/US9562098B2/en active Active
-
2016
- 2016-12-21 US US15/386,998 patent/US10364287B2/en active Active
-
2018
- 2018-09-28 CY CY181101006T patent/CY1120707T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170114136A1 (en) | 2017-04-27 |
| PT2536764T (pt) | 2018-08-10 |
| WO2011101791A1 (en) | 2011-08-25 |
| LT2536764T (lt) | 2018-10-25 |
| CA2788544C (en) | 2019-03-05 |
| EP3428192A1 (en) | 2019-01-16 |
| TR201811185T4 (tr) | 2018-08-27 |
| ES2896149T3 (es) | 2022-02-24 |
| EP2536764A1 (en) | 2012-12-26 |
| US20130078236A1 (en) | 2013-03-28 |
| ES2680570T3 (es) | 2018-09-10 |
| CY1120707T1 (el) | 2019-12-11 |
| US9562098B2 (en) | 2017-02-07 |
| US8785604B2 (en) | 2014-07-22 |
| JP2013519389A (ja) | 2013-05-30 |
| SI2536764T1 (sl) | 2018-11-30 |
| JP5992340B2 (ja) | 2016-09-14 |
| US20150071916A1 (en) | 2015-03-12 |
| EP3428192B1 (en) | 2021-08-11 |
| HRP20181360T1 (hr) | 2018-11-02 |
| EP2536764B1 (en) | 2018-07-04 |
| US10364287B2 (en) | 2019-07-30 |
| DK2536764T3 (en) | 2018-09-17 |
| CA2788544A1 (en) | 2011-08-25 |
| SMT201800462T1 (it) | 2018-11-09 |
| HUE039677T2 (hu) | 2019-01-28 |
| RS57667B1 (sr) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE039677T2 (hu) | Humanizált anti-CD28-ellenanyagok | |
| IL220404A (en) | Antiseptic antibodies | |
| AP4082A (en) | Anti-cd40 antibodies | |
| IL222222A0 (en) | Antibodies against csf-1r | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| HUE068973T2 (hu) | Interleukin-31 monoklonális ellenanyag | |
| IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201020738D0 (en) | Antibodies | |
| PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
| GB201002238D0 (en) | Antibodies | |
| ZA201208136B (en) | Humanized il-25 antibodies | |
| GB201005062D0 (en) | Antibodies | |
| GB201020751D0 (en) | Antibodies |